Skip to content
OpenCapital
Get started

Krystal Biotech, Inc. KRYS Cash Cash Equivalents And Debt Securities Available For Sale Amortized Cost

Other financials

Income statement

See full
Revenue$116.4M+31.9%
Operating income$53.7M+48.1%
Net income$55.9M+56.5%
EPS (diluted)$1.83+52.5%

Balance sheet

See full
Cash & equivalents$501.3M+62.4%
Total debt$9.1M-5.7%
Total equity$1.3B+29.7%
Total assets$1.4B+30.0%

Cash flow

See full
Operating cash flow$80.4M+160%
CapEx$7.1M+15.2%
Free cash flow$73.2M+196%

Valuation

See full
Market cap$10.26B+45.4%
Enterprise value$9.77B+44.2%
P/E45.6×-11.3×
P/S24.6×+3.4×

Profitability

See full
Operating margin42.8%+10.2pp
Net margin53.9%+16.7pp
FCF margin56.9%+16.5pp

Returns & leverage

See full
Return on equity19.9%+6.0pp
Debt / equity0×0.0×
Current ratio9.5×-0.2×

Where this comes from

Reported directly by Krystal Biotech, Inc. in its filing.

Tagged under the XBRL concept krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost.

The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Krystal Biotech, Inc.'s cash cash equivalents and debt securities available for sale amortized cost.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Krystal Biotech, Inc.'s cash cash equivalents and debt securities available for sale amortized cost?
Krystal Biotech, Inc. (KRYS) reported cash cash equivalents and debt securities available for sale amortized cost of $1.02B in Q1 2026.
How has Krystal Biotech, Inc.'s cash cash equivalents and debt securities available for sale amortized cost changed year-over-year?
Krystal Biotech, Inc.'s cash cash equivalents and debt securities available for sale amortized cost increased by 33.0% year-over-year, from $764.64M to $1.02B.
What is the long-term trend for Krystal Biotech, Inc.'s cash cash equivalents and debt securities available for sale amortized cost?
Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s cash cash equivalents and debt securities available for sale amortized cost has grown at a 28.6% compound annual growth rate (CAGR), from $271.26M to $954.68M.